AIDX
20/20 Biolabs, Inc. Common StockNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$10.27M
P/E Ratio
—
EPS
$-0.36
Beta
-0.42
52W High
$50.00
52W Low
$0.90
50-Day MA
$1.68
200-Day MA
$2.74
Dividend Yield
—
Profit Margin
-279.10%
Forward P/E
—
PEG Ratio
—
About 20/20 Biolabs, Inc. Common Stock
20/20 Biolabs, Inc. (AIDX) is an innovative biotechnology firm committed to revolutionizing genomic research and diagnostics through its advanced laboratory services. With a keen focus on enhancing the accuracy and efficiency of genetic testing for clinical and research purposes, the company is poised to be a leader in the molecular diagnostics landscape. By leveraging state-of-the-art technologies, 20/20 Biolabs is strategically positioned to capitalize on the growing demand for personalized medicine and genomic data. Its strong market presence and forward-thinking initiatives underscore a compelling growth outlook within the rapidly evolving biotechnology sector.
Fundamentals
| Revenue (TTM) | $1.84M |
| Gross Profit (TTM) | 501,630 |
| EBITDA | $-3.92M |
| Operating Margin | -408.50% |
| Return on Equity | -354.60% |
| Return on Assets | -58.90% |
| Revenue/Share (TTM) | $0.33 |
| Book Value | $-0.01 |
| Price-to-Book | 317.43 |
| Price-to-Sales (TTM) | 5.57 |
| EV/Revenue | 5.21 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -36.20% |
| Shares Outstanding | $10.48M |
| Float | $8.66M |
| % Insiders | 34.73% |
| % Institutions | 2.83% |
Historical Volatility
HV 10-Day
111.58%
HV 20-Day
85.01%
HV 30-Day
80.22%
HV 60-Day
99.73%
HV Rank
—
Volatility is currently expanding
More HEALTHCARE Stocks
Data last updated: 5/25/2026